A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A [sitagliptin/metformin] for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM).

Trial Profile

A Randomized, Double-Blind, Active-Comparator Controlled, Clinical Trial to Study the Efficacy and Safety of MK0431A [sitagliptin/metformin] for the Treatment of Patients With Type 2 Diabetes Mellitus (T2DM).

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Jun 2017

At a glance

  • Drugs Metformin/sitagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Merck & Co
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 01 Jul 2011 Results published in the Diabetes, Obesity and Metabolism.
    • 18 Oct 2009 Results presented at the 20th World Diabetes Congress (WDC).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top